BIOA/ 10/22/2025 · 6:40 AM Citi Upgrades BioAge Labs Stock on Promising Obesity Drug Potential Citi analyst upgrades BioAge Labs to Buy with $10 price target, citing BGE-102 obesity drug as potentially game-changing treatment option.
